## Zimbabwe

### Tuberculosis profile

#### Population 2018

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>30 (22–39) 210 (155–272)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>19 (14–24) 130 (96–169)</td>
</tr>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>1.5 (1.1–2) 10 (7.4–14)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>1.1 (0.69–1.7) 7.7 (4.8–11)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>3.5 (2.4–4.8) 24 (16–33)</td>
</tr>
</tbody>
</table>

#### HIV-negative TB mortality

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases</td>
<td>3.9% (3.5–4.3)</td>
</tr>
<tr>
<td>Previously treated cases</td>
<td>14% (8.9–20)</td>
</tr>
</tbody>
</table>

#### Tuberculosis profile 2018

<table>
<thead>
<tr>
<th>Number</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>1.5 (1.1–2) 10 (7.4–14)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>1.1 (0.69–1.7) 7.7 (4.8–11)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>3.5 (2.4–4.8) 24 (16–33)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

| New cases | 3.9% (3.5–4.3) |
| Previously treated cases | 14% (8.9–20) |

#### TB case notifications, 2018

| Total new and relapse | 25,204 |
| - % tested with rapid diagnostics at time of diagnosis | 87% |
| - % with known HIV status | 94% |
| - % pulmonary | 89% |
| - % bacteriologically confirmed | 54% |
| - % children aged 0-14 years | 6% |
| - % women | 36% |
| - % men | 58% |
| Total cases notified | 25,775 |

#### Universal health coverage and social protection

| TB treatment coverage (notified/estimated incidence), 2018 | 83% (64–110) |
| TB patients facing catastrophic total costs, 2018 | 80% (74–95) |
| TB case fatality ratio (estimated mortality/estimated incidence), 2018 | 15% (10–22) |

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New and relapse cases registered in 2017</strong></td>
<td>83%</td>
</tr>
<tr>
<td><strong>Previously treated cases, excluding relapse, registered in 2017</strong></td>
<td>83%</td>
</tr>
<tr>
<td><strong>MDR/RR-TB cases started on second-line treatment in 2016</strong></td>
<td>57%</td>
</tr>
<tr>
<td><strong>XDR-TB cases started on second-line treatment in 2016</strong></td>
<td>0%</td>
</tr>
</tbody>
</table>

#### TB financing, 2019

| National TB budget (US$ millions) | 41 |

#### Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-06

Data: www.who.int/tb/data